Watch stocks you care about
The single, easiest way to keep track of all the stocks that matter...
Your own personalized stock watchlist!
It's a 100% FREE Motley Fool service...
Although we don't believe in timing the market or panicking over market movements, we do like to keep an eye on big changes -- just in case they're material to our investing thesis.
What: Shares of VIVUS (NASDAQ: VVUS ) , a biopharmaceutical company developing therapies to treat unmet medical needs such as obesity and sexual health, nosedived as much as 15% after reporting disappointing third-quarter earnings results.
So what: For the quarter, VIVUS recognized $27.4 million in revenue, although $21 million came from its licensing agreement to commercialize and market erectile dysfunction drug Spedra from Menarini Group in more than 40 European countries. Obesity drug Qsymia, on the other hand, delivered just $6.4 million in sales. Net loss rose 19% to $48.2 million, or $0.48 per share. By comparison, Wall Street was forecasting a narrower loss of just $0.39 per share. VIVUS also announced that it would be reducing its workforce by 17%, or 20 employees, excluding its sales force, and improving efficiencies in other areas of its operations to produce cost-savings of $6 million to $8 million by the end of next year.
Now what: Amid the announced licensing agreements with Menarini Group to market Spedra and Auxilium Pharmaceuticals to market Stendra, and underneath its cost reduction plan, investors really just wanted to see Qsymia sales improve and they hardly budged. Through the first nine months of the year, Qsymia sales have totaled just a paltry $16 million, and we can't really blame insurers anymore because many of them have gotten on board by covering Qsymia. Qsymia certainly offered the most impressive weight-loss reduction percentages in clinical trials relative to Arena Pharmaceuticals' (NASDAQ: ARNA ) Belviq, but the concern has always been that Belviq's more favorable safety profile would trump Qsymia's weight-loss advantage. Thus far both drugs have been somewhat of a bust, but I still feel Belviq has the slight upper hand in this battle. With that being said, I'm still not personally touching VIVUS here even after today's drop.
Tired of the hype? Check out this incredible growth stock instead!
Are you growing tired of obesity stocks not meeting lofty expectations? Then maybe its time to check out this incredible tech stock which is growing twice as fast as Google and Facebook, and more than three times as fast as Amazon.com and Apple. Watch our jaw-dropping investor alert video today to find out why The Motley Fool's chief technology officer is putting $117,238 of his own money on the table, and why he's so confident this company will be a huge winner in 2013 and beyond. Just click here to watch!